GMDC’s Doug Blough passes away
COLORADO SPRINGS, Colo. Doug Blough, director of creative services for the Global Market Development Center, passed away Saturday after a battle against pancreatic cancer.
During his tenure at GMDC, Blough had been credited with creating the face of the organization, creating and managing all copywriting, graphic design and art direction. Blough also played a central role in the production and design of GMDC conferences, graphics and signage, as well as photography. In addition, for several years Blough also handled public relations duties for GMDC.
Doug received an AA in fine arts from Lorain County (Ohio) Community College, a BFA in design from Bowling Green State University and completed coursework for an MEd also at Bowling Green. Prior to joining GMDC in 1999, Blough had owned and managed one of Colorado Springs’ leading graphic design firms for 24 years.
Blough’s friends remember well his love of the outdoors and the Pittsburgh Steelers.
Blough is survived by his wife, Linda, his two children, Amanda and Justin, and two grandchildren.
A memorial service will be held Friday, March 28 at the Mountain View United Methodist Church located at:1101 Rampart Range Road,Woodland Park, Colorado80863at 3 p.m. MST.
The family has asked that in lieu of flowers donations be made to: The Blough Children Educational Fundc/o US Bank6 South Tejon StreetColorado Springs, Colorado 80903Attention: L. Specht
Canada court blocks sale of generic form of Lipitor
NEW YORK Canada’s appeals court ruled in favor of Pfizer not allowing Ranbaxy Labs to produce the generic version of the drug Lipitor, according to published reports.
The decision overturned a ruling made by lower courts that stated that the patent could not prohibit Ranbaxy from selling a cheaper version of Lipitor (atorvastin calcium), which is used to fight cholesterol.
The appeals court of Canada decided that Ranbaxy could manufacture its product as soon as Pfizer’s product expires in 2010, which leads many to believe that this decision will push Ranbaxy to take the matter to the Supreme Court of Canada.
McCain’s healthcare plan suggests a loss for pharmaceutical companies
WASHINGTON John McCain’s healthcare plan, with a call to purchase drugs in Canada, may cost American pharmaceutical companies billions of dollars, according to published reports.
According to McCain, the Republican presidential candidate, “The problem is not that most Americans lack adequate health insurance, the biggest problem with the American healthcare system is that it costs too much.”
McCain’s health policy would allow citizens to purchase medicines legally from Canada, which would make them more affordable for the reported 47 million Americans that don’t have health coverage.
According to published reports, such drugs as Pfizer’s Lipitor, known as the world’s biggest selling drug, costs $60.78 for a 30-day supply of 20 mg pills on CanadaDrugs.com, whereas Drugstore.com in the U.S. sells the same pill in the same amount for $119.99.
The new policy is predicted to cost drug makers—like Pfizer—about $40 billion over 10 years, according to a report by the Congressional Budget Office.